Technology from Abcam

Size: px
Start display at page:

Download "Technology from Abcam"

Transcription

1

2 CD2 (EP222) CD2 is one of the earliest T-cell lineage restricted antigens to appear during T-cell differentiation and only rare CD2+ cells can be found in the bone marrow. Anti-CD2 is a pan-t-cell antigen marker. Anti-CD2 is therefore useful for the identification of virtually all normal T-lymphocytes. It is also very useful in the assessment of lymphoid malignancies as it is expressed in the majority of precursor and mature T-cell lymphomas and leukemias. As with other pan-t-cell antigens, CD2 may be aberrantly deleted in some neoplastic T-cell populations, especially peripheral T-cell lymphomas. When combined with anti-cd25, anti-cd2 may assist in the identification of systemic mastocytosis and mastocytic leukemia. Above: Anti-CD2 stains angioimmunoblastic T-cell lymphoma cells in cytoplasmic and perinuclear Golgi pattern. 0.1 ml, concentrate...102r ml, concentrate...102r-15 1 ml, concentrate...102r-16 1 ml, prediluted...102r-17 7 ml, prediluted...102r-18 Positive control slides...102s, membranous Control Tonsil Desmin (EP15) Anti-desmin detects a protein that is expressed by cells of normal smooth, skeletal, and cardiac muscles. It has been suggested that desmin is primarily located at or near the periphery of Z lines in striated muscle fibrils. In smooth muscle, desmin interconnects cytoplasmic dense bodies with membrane bound dense plaques. Anti-desmin reacts with leiomyomas, leiomyosarcoma, rhabdomyomas, rhabdomyosarcoma, and perivascular cells of glomus tumors of the skin. This antibody is used to demonstrate the myogenic components/derivation of tumors. Desmin can also be present in myofibroblasts and be focally positive in desmoid fibromatosis. Above: Anti-desmin highlights rhabdomyosarcoma cells in a cytoplasmic pattern. 0.1 ml, concentrate...243r ml, concentrate...243r-15 1 ml, concentrate...243r-16 1 ml, prediluted...243r-17 7 ml, prediluted...243r-18 Positive control slides...243s Control Skeletal muscle 2

3 ERG (EP111) ERG is a member of the erythroblastosis virus E26 transforming sequence (ETS) transcription factor gene family, which also includes FLI-1 and ETS-1. ERG is expressed in lymphocytes and endothelial cells and regulates endothelial apoptosis and angiogenesis. ERG has been found to be expressed in both benign and malignant vascular tumors. Anti-ERG was found to have high sensitivity for vascular neoplasms. ERG expression has been observed in prostate carcinomas and high-grade prostatic intraepithelial neoplasia (HGPIN). ERG positivity in any other epithelial tumor other than prostate carcinoma is extremely rare. In a study of all carcinomas of the breast, gastrointestinal tract, gynecologic system, kidney, lung, ovary, pancreas, salivary glands, skin, thyroid, and testis were negative for ERG. ERG has also been observed to be positive in a minority of Ewing sarcomas. This is caused by a chromosomal rearrangement which fuses the EWSR1 gene with the ERG gene (EWSR 1:ERG). ERG has also been observed to stain some meningiomas due to cross reactivity with FLI-1. Above: Anti-ERG decorates nuclei of prostatic carcinoma. 0.1 ml, concentrate...434r ml, concentrate...434r-15 1 ml, concentrate...434r-16 1 ml, prediluted...434r-17 7 ml, prediluted...434r-18 Positive control slides...434s Visualization Nuclear Control Tonsil, hemangioma FSH (EP257) Follicle-stimulating hormone (FSH) is a member of the pituitary glycoprotein hormone family which includes luteinizing hormone, chorionic gonadotropin, and thyroid-stimulating hormone. Follicle-stimulating hormone enables ovarian folliculogenesis to the antral follicle stage and is essential for Sertoli cell proliferation and maintenance of sperm quality in the testis. Members of the pituitary glycoprotein hormone family consist of a shared alpha chain and a beta chain encoded by a separate gene. The FSHB gene encodes the beta subunit of follicle stimulating hormone. Anti-FSH is a useful marker in classification of pituitary tumors and the study of pituitary disease, as it reacts with FSH-producing cells (gonadotrophs). Above: Rabbit monoclonal anti-fsh displays pituitary adenoma cells. 0.1 ml, concentrate...207r ml, concentrate...207r-15 1 ml, concentrate...207r-16 1 ml, prediluted...207r-17 7 ml, prediluted...207r-18 Positive control slides...207s Control Pituitary 3

4 Granzyme B (EP230) Granzymes are serine proteases, which are stored in specialized lytic granules of cytotoxic T-lymphocytes and in natural killer cells. Anti-granzyme B has been useful in the identification of natural killer/t-cell lymphoma, as well as anaplastic large cell lymphoma. Above: Anti-granzyme B shows cytotoxic granules in the cytoplasm of angioimmunoblastic T-cell lymphoma cells. 0.1 ml, concentrate...262r ml, concentrate...262r-15 1 ml, concentrate...262r-16 1 ml, prediluted...262r-17 7 ml, prediluted...262r-18 Positive control slides...262s Control Spleen, anaplastic large cell lymphoma Kappa (EP171) Anti-kappa detects surface immunoglobulin on normal and neoplastic B-cells. In paraffin-embedded tissue, anti-kappa exhibits strong staining of kappa-positive plasma cells and cells that have absorbed exogenous immunoglobulins. When dealing with B-cell neoplasms, the determination of light chain ratios remains the centerpiece. Most B-cell lymphomas express either kappa or lambda light chains, whereas reactive proliferations display a mixture of kappa and lambda positive cells. If only a single light chain type is detected, a lymphoproliferative disorder exists. Above: Anti-kappa light chain demonstrates kappa producing plasma cells in the tonsilar tissue. 0.1 ml, concentrate...274r ml, concentrate...274r-15 1 ml, concentrate...274r-16 1 ml, prediluted...274r-17 7 ml, prediluted...274r-18 Positive control slides...274s Control Tonsil 4

5 Lambda (EP172) Anti-lambda detects surface immunoglobulin on normal and neoplastic B-cells. Anti-lambda staining is seen in B-cell follicles of human lymphoid tissue. When dealing with B-cell neoplasms, the determination of light chain ratios remains helpful. Most B-cell lymphomas express either kappa or lambda light chains, whereas reactive proliferations display a mixture of kappa and lambda positive cells. If only a single light chain type is detected, a lymphoproliferative disorder is very likely. Above: Plasma cells in the tonsil are highlighted by the anti-lambda light chain. 0.1 ml, concentrate...277r ml, concentrate...277r-15 1 ml, concentrate...277r-16 1 ml, prediluted...277r-17 7 ml, prediluted...277r-18 Positive control slides...277s Control Tonsil Mammaglobin (EP249) Mammaglobin (10 kd) is a breast-associated glycoprotein distantly related to secretoglobin family that includes human uteroglobin and lipophilin. Mammaglobin mrna is present in high levels in human breast cancer cell lines, which has been shown to be a sensitive marker of breast cancer. When combined with other breast-restricted markers such as GCDFP-15, an overall sensitivity for breast carcinoma of 84% has been achieved. Anti-mammaglobin can also be used to determine breast origin in the setting of metastatic carcinoma. Above: Anti-mammaglobin illustrates the protein expression in the cells of invasive ductal carcinoma of the breast. 0.1 ml, concentrate...280r ml, concentrate...280r-25 1 ml, concentrate...280r-26 1 ml, prediluted...280r-27 7 ml, prediluted...280r-28 Positive control slides...280s Control Breast carcinoma 5

6 Napsin A (EP205) Napsin is a pepsin-like aspartic proteinase, in the A1 clan of the AA clade of proteinases. There are two closely related napsins, napsin A and napsin B. Napsin A is expressed as a single chain protein with the molecular weight of approximately 38 kda. Immunohistochemical studies revealed high expression levels of napsin A in human lung and kidney but low expression in spleen. Napsin A is expressed in type II pneumocytes and in adenocarcinomas of lung. The high specificity expression of napsin A in adenocarcinomas of lung is useful to distinguish primary lung adenocarcinomas from adenocarcinomas of other organs. Above: Lung adenocarcinoma is strongly and diffusely positive for anti-napsin A. 0.1 ml, concentrate...352r ml, concentrate...352r-15 1 ml, concentrate...352r-16 1 ml, prediluted...352r-17 7 ml, prediluted...352r-18 Positive control slides...352s Control Lung adenocarcinoma, kidney, renal cell carcinoma SOX-10 (EP268) Sry-related HMG-BOX gene 10 (SOX-10) is a nuclear transcription factor that participates in neural crest development and in the specification and differentiation of cells of melanocytic lineage. It has been recently shown to be a sensitive marker of melanoma, including conventional, spindled, and desmoplastic subtypes. SOX-10 was expressed by metastatic melanomas in sentinel lymph nodes, but not by other lymph node components such as dendritic cells, which usually express S100 protein. Anti-SOX-10 has been shown to be superior to all other immunostains in detecting residual invasive and in situ melanoma. Anti-SOX-10 is also a useful marker in detecting both the in situ and invasive components of desmoplastic melanoma. It is known that the commonly used melanoma markers, anti-hmb-45 and anti-melan A, are poorly expressed in desmoplastic melanomas while it has been reported that anti-sox-10 was moderately to strongly expressed in almost all desmoplastic melanomas. SOX-10 is diffusely expressed in schwannomas and neurofibromas. SOX-10 presence was not identified in any other mesenchymal and epithelial tumors except for myoepitheliomas and diffuse astrocytomas. Above: SOX-10 rabbit monoclonal antibody highlights tumor cells of desmoplastic melanoma. 0.1 ml, concentrate...383r ml, concentrate...383r-15 1 ml, concentrate...383r-16 1 ml, prediluted...383r-17 7 ml, prediluted...383r-18 Positive control slides...383s Visualization Nuclear Control Melanoma, skin melanocytes 6

7 TTF-1 (EP229) Anti-TTF-1 (Thyroid Transcription Factor 1) is useful in differentiating primary adenocarcinoma of the lung from metastatic carcinomas originating in the organs rather than thyroid, germ cell tumors, and malignant mesothelioma. It can also be used to differentiate small cell lung carcinoma from lymphoid infiltrates. TTF-1 labeling is also seen in thyroid and thyroid-derived tumors. TTF-1 immunostaining is useful in the differentiation between pulmonary and nonpulmonary origin of adenocarcinomas in malignant effusions. TTF-1 staining is very reliable in discerning whether a brain metastasis has arisen from a pulmonary or nonpulmonary site, particularly when dealing with adenocarcinomas and large cell carcinomas. Above: Lung adenocarcinoma strongly and diffusely express TTF-1 protein in the nuclei of the tumor cells. 0.1 ml, concentrate...343r ml, concentrate...343r-15 1 ml, concentrate...343r-16 1 ml, prediluted...343r-17 7 ml, prediluted...343r-18 Positive control slides...343s Visualization Nuclear Control Lung adenocarcinoma Cell Marque + RabMAb Portfolio Rabbit Monoclonal Primary Antibodies Coming Soon! BCL6 (EP278) CD19 (EP169) GLUT1 (EP141) Glycophorin A (EP213) IMP3 (EP286) MCM3 (EP202) Myogenin (EP162) Olig2 (EP112) SATB2 (EP281) WT1 (EP122) Also Available BCL2 (E17) c-myc (EP121) Caldesmon (E89) Calponin-1 (EP798Y) CD1a (EP3622) CD4 (EP204) CD5 (EP77) CD14 (EPR3653) CD21 (EP3093) CD99 (EPR3097Y) CD117, c-kit (YR145) CDX-2 (EPR2764Y) Cyclin D1 (EP12) Cytokeratin 5 (EP1601Y) Cytokeratin 10 (EP97) E-cadherin (EP700Y) Estrogen Receptor (EP1) Factor XIIIa (EP3372) GCDFP-15 (EP1582Y) GFAP (EP672Y) Hemoglobin A (EPR3608) Her2/Neu (EP3) MyoD1 (EP212) PAX-5 (EP156) PMS2 (EPR3947) Progesterone Receptor (Y85) PU.1 (EPR3158Y) S100A1 (EP184) Thyroid Peroxidase (EP159) 7

8 Rev Sigma-Aldrich Co. LLC. All rights reserved. SIGMA-ALDRICH and Cell Marque are trademarks of Sigma-Aldrich Co.

NEW IHC A n t i b o d i e s

NEW IHC A n t i b o d i e s NEW IHC Antibodies TABLE OF CONTENTS NEW IHC ANTIBODIES from Cell Marque CITED1 (5H6).... 1 Claudin 7 (5D10F3).... 1 GATA1 (4F5).... 1 Transgelin (2A10C2).... 1 NEW IHC ANTIBODIES using RabMAb Technology

More information

The Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation

The Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation The Panel Approach to Diagnostics Lauren Hopson International Product Specialist Cell Marque Corporation Cell Marque Rocklin, California About Cell Marque: IVD primary antibody manufacturer Distributors

More information

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,

More information

Financial disclosures

Financial disclosures An update on immunohistochemical markers in mesenchymal neoplasms By Konstantinos Linos MD, FCAP, FASDP Assistant Professor of Pathology Geisel School of Medicine at Dartmouth Dartmouth-Hitchcock Medical

More information

Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement

Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchcock Medical Center

More information

Financial disclosures

Financial disclosures Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchc Geisel School of

More information

Disclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction

Disclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction Disclosures An update on ancillary techniques in the diagnosis of soft tissue tumors. I have nothing to disclose. Andrew Horvai, MD, PhD Clinical Professor, Pathology Introduction Ancillary techniques

More information

Disclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction

Disclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction Disclosures An update on ancillary techniques in the diagnosis of soft tissue tumors. I have nothing to disclose. Andrew Horvai, MD, PhD Clinical Professor, Pathology Introduction Ancillary techniques

More information

Immunohistochemical classification of lung carcinomas and mesotheliomas. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark

Immunohistochemical classification of lung carcinomas and mesotheliomas. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Immunohistochemical classification of lung carcinomas and mesotheliomas Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Endobronchial ultrasound guided transbronchial needle biopsy

More information

The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix

The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

More information

From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport

From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology Songlin Zhang, MD, PhD LSUHSC-Shreveport I have no Conflict of Interest. FNA on Lymphoproliferative

More information

Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2 on all newly diagnosed cases

Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2 on all newly diagnosed cases Adrenal cortical carcinoma Inhibin Synap Melan-A Calretinin Vimentin Chromogr CK7 CK20 Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2

More information

Financial disclosures

Financial disclosures Mesenchymal Neoplasms with Melanocytic Differentiation By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchcock Medical Center Geisel

More information

Diagnostic IHC in lung and pleura pathology

Diagnostic IHC in lung and pleura pathology Diagnostic IHC in lung and pleura pathology Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark WHO 2004 and Web Malignant mesothelioma Epithelioid

More information

DOUBLE STAINS. Toll-Free: Direct:

DOUBLE STAINS. Toll-Free: Direct: DOUBLE STAINS CD61 + CD71 DAB Brown: CD61 Alk. Phos. Red: CD71 Bone Marrow DAB Brown: Megakaryocytes Alk. Phos. Red: Erythroid Precursors 400x CD61 (2f2) 0.1 ml concentrate............. 161M-14 0.5 ml

More information

Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin

Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification

More information

IHC Panels as an Aid in Diagnostic Decision Making

IHC Panels as an Aid in Diagnostic Decision Making IHC Antibody Test Selection Using a Panel Approach Steven Westra B.S. Reagent Product Specialist Leica Biosystems IHC Panels as an Aid in Diagnostic Decision Making Diagnostic Use of Tumors Using Algorithms

More information

Charles Halsey, DVM, PhD, DACVP Pfizer, Inc. IHC Resources

Charles Halsey, DVM, PhD, DACVP Pfizer, Inc. IHC Resources Charles Halsey, DVM, PhD, DACVP Pfizer, Inc. IHC Resources 1 IHC Identification Targets Specimens Controls 2 Tissue controls Trouble Spots 3 The Key to Description IHC Description 4 Intermediate Filaments

More information

ONCOLOGY. Csaba Bödör. Department of Pathology and Experimental Cancer Research november 19., ÁOK, III.

ONCOLOGY. Csaba Bödör. Department of Pathology and Experimental Cancer Research november 19., ÁOK, III. ONCOLOGY Csaba Bödör Department of Pathology and Experimental Cancer Research 2018. november 19., ÁOK, III. bodor.csaba1@med.semmelweis-univ.hu ONCOLOGY Characteristics of Benign and Malignant Neoplasms

More information

3/24/2017 DENDRITIC CELL NEOPLASMS: HISTOLOGY, IMMUNOHISTOCHEMISTRY, AND MOLECULAR GENETICS. Disclosure of Relevant Financial Relationships

3/24/2017 DENDRITIC CELL NEOPLASMS: HISTOLOGY, IMMUNOHISTOCHEMISTRY, AND MOLECULAR GENETICS. Disclosure of Relevant Financial Relationships DENDRITIC CELL NEOPLASMS: HISTOLOGY, IMMUNOHISTOCHEMISTRY, AND MOLECULAR GENETICS Jason L. Hornick, M.D., Ph.D. Director of Surgical Pathology and Immunohistochemistry Brigham and Women s Hospital Professor

More information

C.L. Davis Foundation Descriptive Veterinary Pathology Course

C.L. Davis Foundation Descriptive Veterinary Pathology Course C.L. Davis Foundation 2015 Descriptive Veterinary Pathology Course IHC Resources IHC Identification Targets Antibodies Antibodies 1 Antibodies Specimens Antigen Retrieval Unmasks antigen epitopes Methods

More information

FOLLICULARITY in LYMPHOMA

FOLLICULARITY in LYMPHOMA FOLLICULARITY in LYMPHOMA Reactive Follicular Hyperplasia Follicular Hyperplasia irregular follicles Follicular Hyperplasia dark and light zones Light Zone Dark Zone Follicular hyperplasia MIB1 Follicular

More information

Case: The patient is a 73 year old woman with vague complaints of dyspepsia and abdominal pain. Upper endoscopy showed features of gastritis and a

Case: The patient is a 73 year old woman with vague complaints of dyspepsia and abdominal pain. Upper endoscopy showed features of gastritis and a Case: The patient is a 73 year old woman with vague complaints of dyspepsia and abdominal pain. Upper endoscopy showed features of gastritis and a nodular lesion in the body of the stomach. The patient

More information

Single and Multiplex Immunohistochemistry

Single and Multiplex Immunohistochemistry Single and Multiplex Immunohistochemistry Steve Westra, BS Reagent Product Specialist Leica Biosystems IHC Theory Polyclonal vs Monoclonal Polyclonal reagents Detect a multitude of epitopes Batch to batch

More information

Lung Tumor Cases: Common Problems and Helpful Hints

Lung Tumor Cases: Common Problems and Helpful Hints Lung Tumor Cases: Common Problems and Helpful Hints Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona Society of Pathologists

More information

ACCME/Disclosures. Diagnosing Mesothelioma in Limited Tissue Samples. Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016

ACCME/Disclosures. Diagnosing Mesothelioma in Limited Tissue Samples. Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016 Diagnosing Mesothelioma in Limited Tissue Samples Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016 Sanja Dacic, MD, PhD University of Pittsburgh ACCME/Disclosures GENERAL RULES

More information

Kimberly Rohan ANP-BC, AOCN Nurse Practitioner Edward Cancer Center

Kimberly Rohan ANP-BC, AOCN Nurse Practitioner Edward Cancer Center Kimberly Rohan ANP-BC, AOCN Nurse Practitioner Edward Cancer Center Objective The nurse will be able to explain biomarkers and their implications to patient s prescribed treatment plan Biomarkers Use in

More information

Presentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98

Presentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98 Presentation material is for education purposes only. All rights reserved. 2011 URMC Radiology Page 1 of 98 Radiology / Pathology Conference February 2011 Brooke Koltz, Cytopathology Resident Presentation

More information

NEOPLASIA-I CANCER. Nam Deuk Kim, Ph.D.

NEOPLASIA-I CANCER. Nam Deuk Kim, Ph.D. NEOPLASIA-I CANCER Nam Deuk Kim, Ph.D. 1 2 Tumor in the hieroglyphics of the Edwin Smith papyrus (1,600 B.C., Breasted s translation 1930) 3 War on Cancer (National Cancer Act, 1971) 4 Cancer Acts in Korea

More information

External Quality Assessment of melanocytic marker analyses NordiQC experience

External Quality Assessment of melanocytic marker analyses NordiQC experience External Quality Assessment of melanocytic marker analyses NordiQC experience Jan Klos MD, Department of Pathology Stavanger University Hospital Norway 1 Content 18 Runs = 2112 submissions between 2001-2014

More information

4/12/2018. MUSC Pathology Symposium Kiawah Island April 18, Jesse K. McKenney, MD

4/12/2018. MUSC Pathology Symposium Kiawah Island April 18, Jesse K. McKenney, MD MUSC Pathology Symposium Kiawah Island April 18, 2018 Jesse K. McKenney, MD 1 Urothelial Carcinoma with Alternative Differentiation 2 Urothelial Carcinoma with Alternative Differentiation Recognition as

More information

Immunohistochemical Evaluation of Necrotic Malignant Melanomas

Immunohistochemical Evaluation of Necrotic Malignant Melanomas Anatomic Pathology / EVALUATION OF NECROTIC MALIGNANT MELANOMAS Immunohistochemical Evaluation of Necrotic Malignant Melanomas Daisuke Nonaka, MD, Jordan Laser, MD, Rachel Tucker, HTL(ASCP), and Jonathan

More information

Tumores de células pequeñas, redondas y azules: diagnóstico diferencial cuando el tiempo apremia

Tumores de células pequeñas, redondas y azules: diagnóstico diferencial cuando el tiempo apremia Tumores de células pequeñas, redondas y azules: diagnóstico diferencial cuando el tiempo apremia Sílvia Bagué Servei de Patologia Hospital de Sant Pau Barcelona Soft tissue sarcomas Heterogeneous group

More information

Classification of the unknown primary tumour: the primary IHC panel

Classification of the unknown primary tumour: the primary IHC panel CIQC/CAP-ACP SEMINAR 2013: DIAGNOSTIC IHC AND MOLECULAR PATHOLOGY Classification of the unknown primary tumour: the primary IHC panel Aalborg University Hospital Denmark Tumours of unknown origin: Histology

More information

TEST MENU BY SPECIALTY

TEST MENU BY SPECIALTY 1 TEST MENU BY SPECIALTY Breast Pathology Surgical excisions, needle core biopsies, and plastic surgery accepted from all sites Assessment of margins Axillary lymph node dissections Sentinel lymph nodes

More information

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Schedule of ccreditation United Kingdom ccreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK External Quality ssessment Services for Cancer Diagnostics CIC Issue No: 005

More information

Immunohistochemical classification of the unknown primary tumour (UPT) Part I. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark

Immunohistochemical classification of the unknown primary tumour (UPT) Part I. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Immunohistochemical classification of the unknown primary tumour (UPT) Part I Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Tumours of unknown origin: Histology Brain tumour - biopsy

More information

57th Annual HSCP Spring Symposium 4/16/2016

57th Annual HSCP Spring Symposium 4/16/2016 An Unusual Malignant Spindle Cell Lesion to Involve the Breast Erinn Downs-Kelly, D.O. Associate Professor of Pathology University of Utah & ARUP Laboratories No disclosures Case 39 y/o female with no

More information

Breast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark

Breast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark Breast cancer: IHC classification Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark http://upload.wikimedia.org/wikipedia/commons/1/1a/breast.svg

More information

Cutaneous metastases. Thaddeus Mully. University of California, San Francisco Professor, Departments of Pathology and Dermatology

Cutaneous metastases. Thaddeus Mully. University of California, San Francisco Professor, Departments of Pathology and Dermatology Cutaneous metastases Thaddeus Mully University of California, San Francisco Professor, Departments of Pathology and Dermatology DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Thaddeus Mully Course C005 Essential

More information

Immunopathology of Lymphoma

Immunopathology of Lymphoma Immunopathology of Lymphoma Noraidah Masir MBBCh, M.Med (Pathology), D.Phil. Department of Pathology Faculty of Medicine Universiti Kebangsaan Malaysia Lymphoma classification has been challenging to pathologists.

More information

Review and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors

Review and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors Review and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors. Monophasic tumors : myoepithelioma, acinic cell carcinoma, and salivary duct carcinoma. Biphasic tumors includes

More information

Enterprise Interest Nothing to declare

Enterprise Interest Nothing to declare Enterprise Interest Nothing to declare Diagnoses one would not like to miss in soft tissue pathology early in your career Marta Sbaraglia, MD Department of Pathology Hospital of Treviso University of Padua

More information

Mody. AIS vs. Invasive Adenocarcinoma of the Cervix

Mody. AIS vs. Invasive Adenocarcinoma of the Cervix Common Problems in Gynecologic Pathology Michael T. Deavers, M.D. Houston Methodist Hospital, Houston, Texas Common Problems in Gynecologic Pathology Adenocarcinoma in-situ (AIS) of the Cervix vs. Invasive

More information

Tumour Structure and Nomenclature. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge

Tumour Structure and Nomenclature. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge Tumour Structure and Nomenclature Paul Edwards Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge Malignant Metastasis Core idea of cancer Normal Cell Slightly

More information

Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar

Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar Link full download:https://getbooksolutions.com/download/test-bank-for-robbinsand-cotran-pathologic-basis-of-disease-9th-edition-by-kumar Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th

More information

Desmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC

Desmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC R/O BCC Sabine Kohler, M.D. Professor of Pathology and Dermatology Dermatopathology Service Stanford University School of Medicine Clinical Information 74 y.o. man with lesion on left side of neck r/o

More information

What I Learned from 3 Cases and 3 Antibodies

What I Learned from 3 Cases and 3 Antibodies What I Learned from 3 Cases and 3 Antibodies Melinda Sanders, M.D Vanderbilt University Medical Center Professor of Pathology Consultant in Breast Pathology Disclosure of Relevant Financial Relationships

More information

Catalog Supplement. Vol. 10.1

Catalog Supplement. Vol. 10.1 Catalog Supplement Vol. 10.1 Introducing New Products from Cell Marque From Passion to Product to Patient. Cell Marque, a Sigma-Aldrich company, is proud to introduce our next wave of innovative products.

More information

CODING TUMOUR MORPHOLOGY. Otto Visser

CODING TUMOUR MORPHOLOGY. Otto Visser CODING TUMOUR MORPHOLOGY Otto Visser INTRODUCTION The morphology describes the tissue of the tumour closest to normal tissue Well differentiated tumours are closest to normal Undifferentiated tumours show

More information

Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar

Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar Link full download: http://testbankair.com/download/test-bank-for-robbins-cotran-pathologic-basis-of-disease-9th-edition-bykumar-abbas-and-aster Test Bank for Robbins and Cotran Pathologic Basis of Disease

More information

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour 7 Omar Abu Reesh Dr. Ahmad Mansour Dr. Ahmad Mansour -Leukemia: neoplastic leukocytes circulating in the peripheral bloodstream. -Lymphoma: a neoplastic process in the lymph nodes, spleen or other lymphatic

More information

Pathology Mystery and Surprise

Pathology Mystery and Surprise Pathology Mystery and Surprise Tim Smith, MD Director Anatomic Pathology Medical University of South Carolina Disclosures No conflicts to declare Some problem cases Kidney tumor Scalp tumor Bladder tumor

More information

Diplomate of the American Board of Pathology in Anatomic and Clinical Pathology

Diplomate of the American Board of Pathology in Anatomic and Clinical Pathology A 33-year-old male with a left lower leg mass. Contributed by Shaoxiong Chen, MD, PhD Assistant Professor Indiana University School of Medicine/ IU Health Partners Department of Pathology and Laboratory

More information

MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site

MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site POLICY: PG0364 ORIGINAL EFFECTIVE: 04/22/16 LAST REVIEW: 07/26/18 MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site GUIDELINES This policy does not certify benefits or authorization

More information

Differential diagnosis of HCC

Differential diagnosis of HCC Hepatocellular Carcinoma Quest for an Ideal Immunohistochemical Panel Sanjay Kakar, MD UCSF Differential diagnosis of HCC Hepatocellular lesions Adenoma, FNH, HG dysplasia Adenocarcinoma CholangioCA, metastasis

More information

Gastric Carcinoma with Lymphoid Stroma: Association with Epstein Virus Genome demonstrated by PCR

Gastric Carcinoma with Lymphoid Stroma: Association with Epstein Virus Genome demonstrated by PCR Gastric Carcinoma with Lymphoid Stroma: Association with Epstein Virus Genome demonstrated by PCR Pages with reference to book, From 305 To 307 Irshad N. Soomro,Samina Noorali,Syed Abdul Aziz,Suhail Muzaffar,Shahid

More information

Dr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology

Dr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology Neoplasia Dr Rodney Itaki Lecturer Anatomical Pathology Discipline University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology General Considerations Overview: Neoplasia uncontrolled,

More information

New Developments in Immunohistochemistry for Gynecologic Pathology

New Developments in Immunohistochemistry for Gynecologic Pathology New Developments in Immunohistochemistry for Gynecologic Pathology Michael T. Deavers, M.D. Professor, Departments of Pathology and Gynecologic Oncology Immunohistochemistry in Gynecologic Pathology Majority

More information

Differential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital

Differential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Differential diagnosis of hematolymphoid tumors composed of medium-sized cells Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Lymphoma classification Lymphoma diagnosis starts with morphologic

More information

Tumor Markers Yesterday, Today & Tomorrow. Steven E. Zimmerman M.D. Vice President & Chief Medical Director

Tumor Markers Yesterday, Today & Tomorrow. Steven E. Zimmerman M.D. Vice President & Chief Medical Director Tumor Markers Yesterday, Today & Tomorrow Steven E. Zimmerman M.D. Vice President & Chief Medical Director Tumor Marker - Definition Substances produced by cancer cells or other cells in response to cancer

More information

What is New in the 2015 WHO Lung Cancer Classification? Zhaolin Xu, MD, FRCPC, FCAP

What is New in the 2015 WHO Lung Cancer Classification? Zhaolin Xu, MD, FRCPC, FCAP What is New in the 2015 WHO Lung Cancer Classification? Zhaolin Xu, MD, FRCPC, FCAP Professor, Dept of Pathology, Dalhousie University, Canada Pulmonary Pathologist and Cytopathologist, QEII HSC Senior

More information

Neoplasia part I. Dr. Mohsen Dashti. Clinical Medicine & Pathology nd Lecture

Neoplasia part I. Dr. Mohsen Dashti. Clinical Medicine & Pathology nd Lecture Neoplasia part I By Dr. Mohsen Dashti Clinical Medicine & Pathology 316 2 nd Lecture Lecture outline Review of structure & function. Basic definitions. Classification of neoplasms. Morphologic features.

More information

The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part I)

The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part I) The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark

More information

Mesothelioma: diagnostic challenges from a pathological perspective. Naseema Vorajee August 2016

Mesothelioma: diagnostic challenges from a pathological perspective. Naseema Vorajee August 2016 Mesothelioma: diagnostic challenges from a pathological perspective Naseema Vorajee August 2016 Naseema.vorajee@nhls.ac.za Pleural diseases (whether neoplastic, reactive or infective) may have similar

More information

Computational Systems Biology: Biology X

Computational Systems Biology: Biology X Bud Mishra Room 1002, 715 Broadway, Courant Institute, NYU, New York, USA L#5:(October-18-2010) Cancer and Signals Outline 1 2 Outline 1 2 Cancer is a disease of malfunctioning cells. Cell Lineage: Adult

More information

Pancreas. Atrophy, acinar cell. Pathogenesis: Diagnostic key features:

Pancreas. Atrophy, acinar cell. Pathogenesis: Diagnostic key features: Pancreas Atrophy, acinar cell Pathogenesis: Decrease in number and/or size of acinar cells may be due to spontaneous or experimentally induced degenerative changes, apoptosis, or a sequel of chronic inflammation.

More information

Neoplasia literally means "new growth.

Neoplasia literally means new growth. NEOPLASIA Neoplasia literally means "new growth. A neoplasm, defined as "an abnormal mass of tissue the growth of which exceeds and is uncoordinated with that of the normal tissues and persists in the

More information

Carcinoma of Unknown Primary (CUP)

Carcinoma of Unknown Primary (CUP) Metasta c Carcinoma of Unknown Primary: Diagnos c Approach Using Immunohistochemistry James R. Conner, MD, PhD Mount Sinai Hospital Toronto, ON Carcinoma of Unknown Primary (CUP) 3-5% of all new malignant

More information

Review of the AP Part II Practical Examination. Dr David Clift Co Chief Examiner

Review of the AP Part II Practical Examination. Dr David Clift Co Chief Examiner Review of the AP Part II Practical Examination Dr David Clift Co Chief Examiner General Remarks The part II practical examination involved 15 cases which were presented with sufficient clinical data to

More information

In Situ Hybridization Immunohistochemistry

In Situ Hybridization Immunohistochemistry 2013-2014 In Situ Hybridization Immunohistochemistry A History of Delivering Superior Products Genemed Biotechnologies, Inc. was founded in 1987 and is located in the center of the South San Francisco

More information

ACR TXIT TM EXAM OUTLINE

ACR TXIT TM EXAM OUTLINE ACR TXIT TM EXAM OUTLINE Major Domain Sub-Domain 1 Statistics 1.1 Study design 1.2 Definitions of statistical terms 1.3 General interpretation & analysis 1.4 Survival curves 1.5 Specificity/sensitivity

More information

Carcinoma of unknown primary origin (CUP) is defined

Carcinoma of unknown primary origin (CUP) is defined REVIEW ARTICLE Metastatic Carcinoma of Unknown Primary: Diagnostic Approach Using Immunohistochemistry James R. Conner, MD, PhD and Jason L. Hornick, MD, PhD Abstract: Carcinoma of unknown primary origin

More information

Nordic Immunohistochemical Quality Control

Nordic Immunohistochemical Quality Control Nordic Immunohistochemical Quality Control Immunohistochemistry in the classifiation of neoplasias of the alimentary tract & External Quality Assurance of Immunohistochemistry for GI cancer markers Mogens

More information

SHN-1 Human Digestive Panel Test results

SHN-1 Human Digestive Panel Test results SHN-1 Human Digestive Panel Test results HN-30 tongue HN-24 salivary gland HN-12 larynx HN-28 esophagus HN-29 stomach HN-20 pancreas HN-13 liver HN-14 gall bladder HN-27-1 duodenum HN-27-2 ileum HN-27-3

More information

ADVANCED STAINING PRODUCT CATALOG. In Situ Hybridization Probes Immunohistochemistry Antibodies Detection Systems Ancillary Reagents

ADVANCED STAINING PRODUCT CATALOG. In Situ Hybridization Probes Immunohistochemistry Antibodies Detection Systems Ancillary Reagents 2017 ADVANCED STAINING PRODUCT CATALOG In Situ Hybridization Probes Immunohistochemistry Antibodies Detection Systems Ancillary Reagents A History of Delivering Superior Products Genemed a wholly-owned

More information

TUMOR M ARKERS MARKERS

TUMOR M ARKERS MARKERS TUMOR MARKERS M.Shekarabi IUMS Definition Many cancers are associated with the abnormal production of some molecules l which h can be measured in plasma. These molecules are known as tumor markers. A good

More information

The unknown primary tumour: IHC classification part I, the primary panel - Antibody selection, protocol optimization, controls and EQA

The unknown primary tumour: IHC classification part I, the primary panel - Antibody selection, protocol optimization, controls and EQA The unknown primary tumour: IHC classification part I, Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark the primary panel - Antibody selection,

More information

Role of immunohistochemistry in the differential diagnosis of malignant small round cell tumor: a study of 38 cases

Role of immunohistochemistry in the differential diagnosis of malignant small round cell tumor: a study of 38 cases International Journal of Research in Medical Sciences Patel A et al. Int J Res Med Sci. 2015 Dec;3(12):3833-3839 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20151452

More information

Oncocytic-Appearing Salivary Gland Tumors. Oncocytic, Cystic, Mucinous, and High Grade Salivary Gland Tumors SALIVARY GLAND FNA: PART II

Oncocytic-Appearing Salivary Gland Tumors. Oncocytic, Cystic, Mucinous, and High Grade Salivary Gland Tumors SALIVARY GLAND FNA: PART II William C. Faquin, MD, PhD Professor of Pathology Harvard Medical School Director of Head and Neck Pathology Massachusetts Eye and Ear Massachusetts General Hospital SALIVARY GLAND FNA: PART II Oncocytic,

More information

Cerebral Parenchymal Lesions: I. Metastatic Neoplasms

Cerebral Parenchymal Lesions: I. Metastatic Neoplasms Chapter 4 Cerebral Parenchymal Lesions: I. Metastatic Neoplasms After one has reasonably ruled out the possibility of a nonneoplastic diagnosis (see Chap. 3), one is left with considering a diagnosis of

More information

The clinically challenging entity of liver metastasis from tumors of unknown primary

The clinically challenging entity of liver metastasis from tumors of unknown primary The clinically challenging entity of liver metastasis from tumors of unknown primary Xuchen Zhang, MD, PhD Associate Professor of Pathology Department of Pathology Yale University School of Medicine Liver

More information

Biopsy Interpretation of Spindle cell proliferations of the Serosa

Biopsy Interpretation of Spindle cell proliferations of the Serosa Biopsy Interpretation of Spindle cell proliferations of the Serosa Richard Attanoos, Cardiff. U.K. Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee)

More information

Urinary Bladder: WHO Classification and AJCC Staging Update 2017

Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Houston Society of Clinical Pathologists 58 th Annual Spring Symposium Houston, TX April 8, 2017 Jesse K. McKenney, MD Classification

More information

The Development of Lymphocytes: B Cell Development in the Bone Marrow & Peripheral Lymphoid Tissue Deborah A. Lebman, Ph.D.

The Development of Lymphocytes: B Cell Development in the Bone Marrow & Peripheral Lymphoid Tissue Deborah A. Lebman, Ph.D. The Development of Lymphocytes: B Cell Development in the Bone Marrow & Peripheral Lymphoid Tissue Deborah A. Lebman, Ph.D. OBJECTIVES 1. To understand how ordered Ig gene rearrangements lead to the development

More information

Classification (1) Classification (3) Classification (2) Spindle cell lesions. Spindle cell lesions of bladder (Mills et al.

Classification (1) Classification (3) Classification (2) Spindle cell lesions. Spindle cell lesions of bladder (Mills et al. Non-epithelial tumours and nonepithelial tumour-like lesions of the bladder Dr Jonathan H Shanks The Christie NHS Foundation Trust, Manchester, UK Classification (1) Myofibroblastic proliferations and

More information

Pitfalls in thyroid tumor pathology. Prof.Valdi Pešutić-Pisac MD, PhD

Pitfalls in thyroid tumor pathology. Prof.Valdi Pešutić-Pisac MD, PhD Pitfalls in thyroid tumor pathology Prof.Valdi Pešutić-Pisac MD, PhD Too many or... Tumour herniation through a torn capsule simulating capsular invasion fibrous capsule with a sharp discontinuity, suggestive

More information

Immunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD

Immunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD Immunohistochemistry in Bone and Soft Tissue Tumors Sahar Rassi Zankoul, MD Introduction Bone tumors represent a wide variety of tumors of various origins and malignant potentials. These different tumor

More information

Tumor Markers & Cytopathology

Tumor Markers & Cytopathology Tumor Markers & Cytopathology Objectives: After learning, student should be able to 1. Describe the basic concepts of tumor markers and Asst. Prof. Prasit Suwannalert, Ph.D. (Email: prasit.suw@mahidol.ac.th)

More information

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Royal National Orthopaedic Hospital NHS Trust Brockley Hill Stanmore Middlesex HA7 4LP Contact: Professor Adrienne Flanagan Tel: +44 (0)20

More information

Chapter 9, Part 1: Biology of Cancer and Tumor Spread

Chapter 9, Part 1: Biology of Cancer and Tumor Spread PATHOPHYSIOLOGY Name Chapter 9, Part 1: Biology of Cancer and Tumor Spread I. Cancer Characteristics and Terminology Neoplasm new growth, involves the overgrowth of tissue to form a neoplastic mass (tumor).

More information

Histopathological diagnosis of CUP

Histopathological diagnosis of CUP Histopathological diagnosis of CUP Dr Karin Oien karin.oien@glasgow.ac.uk Disclosure slide Dr Karin Oien has no financial interests in any company mentioned in this presentation. Dr Karin Oien is conducting

More information

Section 14 Other Cancers. Cancer of Unknown 113 Primary Site INTRODUCTION PATHOLOGIC EVALUATION

Section 14 Other Cancers. Cancer of Unknown 113 Primary Site INTRODUCTION PATHOLOGIC EVALUATION Section 14 Other Cancers Cancer of Unknown 113 Primary Site F. Anthony Greco and John D. Hainsworth INTRODUCTION Cancer of unknown primary (CUP) site is a clinical syndrome that includes many types of

More information

Plasma cell myeloma (multiple myeloma)

Plasma cell myeloma (multiple myeloma) Plasma cell myeloma (multiple myeloma) Common lymphoid neoplasm, present at old age (70 years average) Remember: plasma cells are terminally differentiated B-lymphocytes that produces antibodies. B-cells

More information

MT09 - Normal Human Tissue Microarray, FDA

MT09 - Normal Human Tissue Microarray, FDA Reveal Biosciences offers Histochemical Staining, Immunohistochemistry (IHC), In Situ Hybridization (ISH), Whole Slide Imaging, and Quantitative Image Analysis on any TMA MT09 - Normal Human Tissue Microarray,

More information

Neoplasia 2018 lecture 11. Dr H Awad FRCPath

Neoplasia 2018 lecture 11. Dr H Awad FRCPath Neoplasia 2018 lecture 11 Dr H Awad FRCPath Clinical aspects of neoplasia Tumors affect patients by: 1. their location 2. hormonal secretions 3. paraneoplastic syndromes 4. cachexia Tumor location Even

More information

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management. Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician

More information

Objectives. Salivary Gland FNA: The Milan System. Role of Salivary Gland FNA 04/26/2018

Objectives. Salivary Gland FNA: The Milan System. Role of Salivary Gland FNA 04/26/2018 Salivary Gland FNA: The Milan System Dr. Jennifer Brainard Section Head Cytopathology Cleveland Clinic Objectives Introduce the Milan System for reporting salivary gland cytopathology Define cytologic

More information

Surgical Pathology Evening Specialty Conference USCAP 2015

Surgical Pathology Evening Specialty Conference USCAP 2015 Surgical Pathology Evening Specialty Conference USCAP 2015 John R. Goldblum, M.D. Chairman, Department of Pathology, Cleveland Clinic Professor of Pathology, Cleveland Clinic Lerner College of Medicine

More information

How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens

How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens Wenxin Zheng, M.D. Professor of Pathology and Gynecology University of Arizona zhengw@email.arizona.edu http://www.zheng.gynpath.medicine.arizona.edu/index.html

More information